Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

NEUROSHIELD

financed

Closed

Novel small molecule attenuator of neuroinflammation in Parkinson’s Disease

Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on administration of dopamine precursors or analogues. Neuroinflammation is a central hall... see more

31/07/2026

UNL

Unknown Budget

Project leader

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2025-02-01

ERC-2024-POC: ERC PROOF OF CONCEPT GRANTS Objective:ObjectivesThe ERC Proof of Concept Grants aim at facilitating exploration of the commercia...

I+D

Cerrada

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UNL

Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 17 months Date Start: 2025-02-01
End date: 2026-07-31

Project leader

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

participation deadline Sin fecha límite de participación.

Project description Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on administration of dopamine precursors or analogues. Neuroinflammation is a central hallmark of PD, however, no molecule is present in the market to tackle neuroinflammation in PD patients. Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness driving to neuronal death. NEUROSHIELD will address this gap in PD treatment, to ensure an increased quality of life of PD patients, while exploiting this therapeutic market opportunity. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or raised long-term usage complications due to adverse side-effects. NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, different mechanism to the classic NSAID COX-2 inhibitors mechanism. We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation. NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers